Table 4 Top 3 medications considered in disagreement between CG CrCl and eGFR (CKD-EPI)
From: Quality use of medicines in patients with chronic kidney disease
CKD-EPI eGFR | CG Equation | Medication | N (%) |
|---|---|---|---|
Appropriate | Contraindicated | Spironolactone | 229 (27.8) |
Alendronate | 186 (22.5) | ||
Risedronate | 105 (12.7) | ||
Inappropriate dose | Atenolol | 501 (32.3) | |
Metformin | 272 (17.5) | ||
Sitagliptin | 169 (10.9) | ||
Contraindicated | Appropriate | Moxonidine | 270 (30.5) |
Spironolactone | 241 (27.3) | ||
Dapagliflozin | 177 (20) | ||
Inappropriate dose | Moxonidine | 7 (46.7) | |
Metformin | 4 (26.7) | ||
Rivaroxaban | 4 (26.7) | ||
Inappropriate dose | Appropriate | Metformin | 1812 (35.5) |
Fenofibrate | 915 (17.9) | ||
Atenolol | 675 (13.2) | ||
Contraindicated | Rivaroxaban | 13 (52.0) | |
Metformin | 12 (48.0) |